Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age3-17
SponsorJohns Hopkins All Children's Hospital

About this trial

Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg/kg/dose for 2 days, every 6 hours (q6h) DM 0.25 mg/kg/dose for 2 days, and methylprednisolone (MP) 1 mg/kg/dose every 6 hours for 5-days.

To address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 3-17 years

Intensive care unit admission

Treatment for critical asthma

Disqualifiers

History of unrepaired critical congenital heart disease

History of cystic fibrosis

Active tracheostomy dependence

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dexamethasone (0.6mg/kg; Max 16mg) Once Daily

    Drug

    For this intervention, Dexamethasone will be administered at 0.6mg/kg/dose once daily for a maximum dose of 16 mg for 2 days

  • Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours

    Drug

    For this intervention, Dexamethasone will be administered at 0.25mg/kg/dose every 6 hours for a maximum dose of 16 mg for 2 days

  • Methylprednisolone

    Drug

    For this intervention, Methylprednisolone will be administered at 1 mg/kg/dose every 6 hours for a maximum dose of 60 mg for 5 days

Treatment groups

159 Participants
are divided into 3 treatment groups
Group A: Dexamethasone Once Daily Dosing for 2daysActive comparator 1 intervention
Group B: Dexamethasone Every 6-Hours Dosing for 2 daysActive comparator 1 intervention
Group C: Methylprednisolone Every 6-hours Dosing for 5-daysActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Post-Discharge Systemic Corticosteroid Exposure

Aggregate occurrence rate (i.e., risk) of systemic corticosteroid exposures after hospital discharge

Time frame
Within 30 days of hospital discharge
2

Cumulative Adverse Events of Special Interest

Cumulative Adverse Events of Special Interest are inclusive of symptomatic hypertension requiring an antihypertensive agent, symptomatic hyperglycemia requiring insulin, symptomatic agitation requiring antipsychotic agent or sedative administration, adrenal insufficiency, and candidiasis.

Time frame
From enrollment through 30-days following hospital discharge

Secondary outcomes

1

Pediatric Asthma Quality of Life

Pediatric Asthma Quality of Life Questionnaire. Mean scores range from 1 to 7. Higher score indicating higher quality of life.

Time frame
Measured at 30-days post hospital discharge
2

Critical Asthma Adjunct Intervention Free Hours

Critical Asthma Adjunct Intervention Free Hours includes the cumulative number of hours during hospitalization where no critical asthma adjunct interventions are administered.

Time frame
From Enrollment through 30 days post Hospital Discharge

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.